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ABSTRACT

A
novel anthracycline glycoside 2-deoxy-Lfucopyranosyl carminomycinone which is effective for
inhibiting the growth of tumors such as leukemia
L1210.
2 Claims, No Drawings
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DETA ILED DESCRIPTION

CARMINOMYCIN ANALOGUE

BACKGROUND OF TH E INVENTION
1. Field of the Invention
This invention relates to a new anthracycline glyco
side antineoplastic agent and, more particularly, to a
new oxygen analogue of the anthracycline antibiotic
carminomycin.
2. Prior Art
As described in M. G. Brazhnikova et al., J. Antibiot.,
27:254-259 (1974), G. F. Gause et al, Cancer Chemother.
Rep. 58:255-256 (1974), M. C. Wani et al, J. Am. Chem.
Soc. 97:5955-5956 (1975) and West German Pat. No.
2,362,707, the anthracycline glycoside carminomycin is
known to be a clinically useful antineoplastic agent.
However, it produces certain undesirable side effects,
common to many antineoplastics agents, which limit its
use in chemotherapy. In particular, it produces a cumu
lative, dose-related cardiotoxicity which limits the total
dosage that can be administered to a patient and the
duration of treatment.
Preparation of a glycoside of daunorubicin is de
scribed in E, F. Fuchs et al, Carbohydr. Res., 57: C36
(1977). Preparation of glycosides of e-rhodomycinone is
described in H. S. El Khadem et al, J. Med. Chem.,
20:957-960 (1977). Preparation of 2-deoxy-Lfucopyranosyl-e-pyrromycinone and 2-deoxy-D-erythro-pentopyransoly-e-pyrromycinone, - cdaunomycinone, and - carminomycinone and their dio-O-acetyl
derivatives is described in H. S. El Khadem, Carbohydr.
Res., 65: C l (1978).
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The overall reaction scheme of a preferred process
for preparing the novel carminomycin analogue of the
5 invention can be represented as follows:
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SUMMARY OF TH E INVENTION
The present invention provides a new oxygen ana
logue of carminomycin which can be represented by the 40
following formula:
(IV)
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This carminomycin analogue can be prepared by cou 55
pling an appropriate glycosyl halide, namely, 3,4-di-Oacetyl-2,6-dideoxy-a-L-lyxo-hexopyranosyl bromide,
or the corresponding chloride, to carminomycinone.
The resulting acetylated blocked glycoside intermedi
ate is deacetylated to produce the above oxygen ana 60
logue of carminomycin which is effective for inhibiting
the growth of tumors such as leukemia L1210.
The invention also provides a method for inhibiting
the growth of certain mammalian tumors such as L1210 65
leukemia by administering therapuetically effective
amounts of the above compound to experimental ani
mals afflicted with such tumors.

wherein X is Br or Cl.
The starting compound carminomycinone (I) can be
prepared in a conventional manner such as by hydrolyz
ing carminomycine. This can be accomplished by re
fluxing a 0.1 N hydrochloric solution of carminomycin
for 2-3 hours and filtering the precipitate carminomyci
none crystals from the solution.
The glycosyl halide 3,4-di-0-acetyl-2,6-dideoxy-a-Llyxo-hexopyranosyl bromide or chloride (II) coupled
with carminomycinone can be prepared in the manner
as described in H. S. El Khadem et al, Carbohydr. Res.,
58:230-234 (1977). That is, L-fucose tetraacetate is
treated with hydrogen bromide in acetic acid to obtain
the corresponding glycosyl bromide which is treated
with an activated zinc dust suspension at a reduced
temperature, the cold mixture filtered and the filtrate
extracted with chloroform or the like. The resulting
di-O-acetyl-L-fucal is treated with a dry stream of hy
drogen bromide or hydrogen chloride to produce the
desired glycosyl halide.
The coupling reaction is carried out by refluxing one
molar equivalents of carminomycinone and the glycosyl
halide under Koenig-Knorr conditions using a mercuric
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bromide-mercuric cynanide catalyst. The reaction
product is filtered to remove solids and the mercuric
salts. The filtrate is evaporated to dryness to remove the
solvent. The solid residue is dissolved in a suitable sol
vent, such as chloroform, and the resulting solution is
washed to remove remaining mercuric salts. After the
solution is evaporated to dryness, the resulting solid
residue is dissolved in a suitable solvent, such a diethyl
ether, and sugar components which do not react with
carminomycinone are removed in a suitable manner,
such as with a column chromatograph, to yield the
blocked acetylated glycoside intermediate (III).
The glycoside intermediate (III) is deacetylated in a
suitable manner to produce the carminomycin analogue
of the invention. This can be accomplished by dis
solving the acetylated glycoside in a suitable solvent,
such as methanol, and adding the solution to a sodium
methoxide-methanoi solution containing an excess of
sodium methoxide. The desired carminomycinone ana
logue 2-deoxy-L-fucopyranosyl carminomycinone (IV)
is extracted by chloroform or the like.
The compound of the invention can be used as an
active ingredient in pharmaceutical compositions in
cluding a pharmaceutically acceptable carrier. Such
compositions could also include one or more active
antibacterial and/or antineoplastic agents and may be in
any form suitable for the desired mode of administra
tion. For instance, the pharmaceutical composition can
be in a solid form for oral administration, such as tablets,
powders, granules or capsules, liquid form for oral ad
ministration such as syrups, solutions or suspensions and
liquid preparations for parenteral administration, such
as solutions, emulsions, or suspensions.
The pharmaceutical composition is administered in
dosages which provide a concentration of the car
minomycinone glycoside greater than the minimum
inhibitory concentration for the leukemia tumor. The
actual dosage will vary depending on such things as the
formulation of the composition, mode of administration,
age, weight, diet and reaction sensitivities of the af
flicted host, and severity of the tumor. It is well within
the skill of the art, after reviewing the guidelines dis
closed herein, to determine the optimum dosage for a
given situation by using conventional dosage tests.
Without further elaboration, it is believed one skilled
in the art can, by using the preceeaing description,
utilize the present invention in its fullest extent. The
following examples are presented for the purpose of
illustration and should not be construed as 'limitations to
the invention.

1 hour. An additional 200 mg of the glycosyl bromide
was added to the mixture and the mixture refluxed for
another hour. The solution was filtered to remove the
molecular sieves and the mercuric compounds and the
sieves were washed with chloroform. The combined
filtrates were evaporated to dryness, the solid residue
dissolved in chloroform and the resulting solution was
washed several times with a 20% potassium iodide solu
tion to remove remaining mercuric compounds. The
solution was then dried over anhydrous sodium sulfate
and evaporated to dryness. The solid residue was dis
solved in absolute diethyl ether containing a small
amount of chloroform and the solution was applied to a
silica gel column chromatograph (washed with absolute
diethyl ether) to remove sugar components which had
not reacted with carminomycinone. The blocked acetyleted glycoside intermediate (III) was eluded with chlo
roform containing 3% methanol.
The glycoside-containing fractions from the chro
matograph were evaporated to dryness. The solid resi
due was dissolved in 20 ml of methanol and the resulting
solution was added to a freshly prepared, room temper
ature sodium methoxide/methanol solution containing
an excess of sodium methoxide to deacetylate the glyco
side. After 20 minutes, the solution was poured into a
separatory funnel containing a sodium hydrogen sulfate
solution and the desired oxygen analogue of carmino
mycin (IV) was extracted with chloroform. The extract
was dried over anhydrous sodium sulfate and evapo
rated to dryness. The solid residue was dissolved in 40
ml of hoi 95% methanol and the resulting solution was
filtered and reduced in volume to about 10 ml. After
cooling, the crystals were filtered and washed with
ethanol and ether to yield about 100 mg of 2-deoxy-Lfucopyranosyl carminomycinone (IV) having a melting
point of 228°~232° C. Elemental analysis of the material
gave the following results:
Calculated weight percent for C26H 26O 11, 0.5 H 2O:
0 = 59.65, 11=5.20. Found: C =59, H=4.91.
The structure for the glycoside (IV) was confirmed
by its n.m.r. spectrum.
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EXAMPLE 1
Preparation of 2-deoxy-L-fucopyranosyl
carminomycinone

55

300 mg of carminomycin in 30 ml of 0.! N hydrochlo
ric acid was refluxed with stirring for 3 hours. This
solution was cooled and filtered. The wet red crystals 60
were dried in a vacuum desiccator over sodium hydrox
ide overnight to yield about 200 mg of carminomyci
none (I).
A mixture comprising 200 mg carminomycinone, 1.0
g finely divided molecular sieves 3A, 200 mg mercuric 65
bromide, 20 mg mercuric cynnanide, 200 mg 3,4-di-Oacetyl-2,6-dideoxy-a-lyxo hexopyranosyi bromide (II)
and 20 ml tetrahydrofuran was refluxed with stirring for

EXAMPLE 2
Bilogica! Activity
The carminomycinone glycoside prepared by the
procedure described in Example 1 was tested against
transplanted mouse leukemia L 1210 according to the
procedures described in Cancer Chemother, Rep.,
3:1-87, Pari 3 (1972). Two experiments were con
ducted. The mice were given a single treatment in the
first experiment and the mice were given both a single
treatment and a daily injection for 9 days (QD 1—>9) in
the second experiment.
The test results are summarized in Table I. From
these data, it can be seen that the survival time of tumor
bearing animals was increased 86% over the control in
the first experiment and at least one dose for each type
of treatment in the second experiment increased the
survival time by 71%.
From the foregoing description, one skilled in the art
can easily ascertain the essential characteristics of the
invention, and without departing from the spirit and
scope thereof, can make various changes and modifica
tions to adapt it to various usages.
We claim:
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TABLE I

Experiment
No.
Material
1

CG

E FFEC T OF CARMINOMYCINONE
GLYCOSIDE (CG) ON L 1210 LEUKEMIA
Effect
MST, MST,
Dose,
Treatment
Regimen
Days % T /C
m g/kg/day
Once, Day 1

i
l

1
1

2

Control (saline)
CG

i

i

Once, Day 1
i
i
i

i
i

QD 1 — 9
i
1
1
1
1
Control (saline)

12.8
6.4
3.2
1.6
0.8
0.4
—

51.2
25.6
12.8
6.4
3.2
1.6
12.8
6.4
3.2
1.6
0.8
0.4

—

13.0
9.5
8.0
7.5
8.0
7.0
7.0
12.0
11.5
9.5
11.0
8.0
9.0
8.0
12.0
11.0
8.5
8.0
8.0
7.0

Average
Weight
Change, g

Survivors,
Day 5

- 0 .4
-1 .1
-0 .9
-0 .8
+ 1.2
-0 .8
+2.2
- 1 .9
-1 .2
+0.3
+0.7
+0.2
- 0 .6
- 1 .6
- 1 .7
-0 .3
-0 .6
+2.3
+0.6
+ 1.9

6/6
6/6
6/6
6/6
6/6
6/6
10/10
5/6
6/6
6/6
6/6
6/6
6/6
5/6
6/6
5/6
6/6
6/6
6/6
10/10

186
136
114
107
114
107
—

171
164
136
157
114
129
114
171
157
121
114
114
—

Tumor Inoculum: 1G6 ascites cells implanted i.p. into BDFj female mice.
Evaluation: MST = median survival time in days; % T /C = MST treated/MST control X 100.
Criteria: % T /C = 125 considered significant antitumor effect.

2. A method of inhibiting the growth of L 1210 leuke
mia tumors comprising administering to an experimen
tal animal host afflicted with said tumor a composition
including an amount of a compound according to claim
1 sufficient to inhibit the growth of said tumor and a
pharmaceutically acceptable carrier.
* 4c « * #

1. A compound having the formula:
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